NYU’s Institute for Engineering Health: A New Model for Cross-Disciplinary Medical Research

NYU Tandon’s Bold Departure from Traditional Research Models

Academic research has long followed a predictable pattern: gather experts from a single discipline, confine them to a building, and hope for meaningful outcomes. Biology departments focus solely on biology. Engineering departments prioritize engineering. Medical schools treat patients.

NYU is dismantling this siloed approach with its new Institute for Engineering Health. Here, the organizing principle revolves around disease states—not academic fields. Instead of asking, “What can electrical engineers contribute to medicine?,” researchers pose questions like, “What would it take to cure allergic asthma?” They then assemble teams of immunologists, computational biologists, materials scientists, AI researchers, wireless communications engineers, and others to solve the problem.

Early Successes: From Lab to Market

The Institute’s unconventional model is already yielding results. A chemical engineer and an electrical engineer collaborated to develop a device that detects airborne threats—including disease pathogens—which has since become a startup. A visually impaired physician partnered with mechanical engineers to create navigation technology for blind subway riders. Meanwhile, Jeffrey Hubbell, the Institute’s leader and NYU’s vice president for bioengineering strategy, is advancing “inverse vaccines” that could reprogram immune systems to treat conditions like celiac disease and allergies. This work demands expertise in immunology, molecular engineering, and materials science.

Rethinking Medicine’s Core Strategy

Hubbell argues that modern medicine has optimized around a single strategy: developing drugs that block specific molecules or suppress targeted immune responses. Antibody technology has been the cornerstone of this approach. “It’s really fit for purpose for blocking one thing at a time,” he says. The pharmaceutical industry excels at creating these inhibitors, each designed to shut down a particular pathway.

But Hubbell challenges this paradigm. Instead of inhibiting one harmful process at a time, what if researchers could promote beneficial processes that counteract multiple harmful pathways simultaneously? For example:

• In inflammation: Could the immune system be biased toward tolerance rather than blocking inflammatory molecules one by one?
• In cancer: Could pro-inflammatory pathways in the tumor microenvironment overcome multiple immune-suppressive features at once?

A New Toolkit for Medical Breakthroughs

This shift from inhibition to activation requires a fundamentally different set of tools—and researchers. “We’re using biological molecules like proteins, or material-based structures—soluble polymers, supramolecular structures of nanomaterials—to drive these more fundamental features,” Hubbell explains. Mastering these approaches demands expertise across biology, materials science, and immunology—not just one field.

Cultivating the Next Generation of Cross-Disciplinary Researchers

This raises a critical question: How can researchers develop the depth of knowledge required to work across disciplines? The answer, Hubbell suggests, may lie in rethinking education entirely. “There may have been”